Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
U.S. FDA IND approval for the first global MRCT Phase 3 study (MarsLight-11) of IBI363 (PD-1/IL-2a-bias) in squamous NSCLC - lead licensed asset advanced into…
With Takeda deal, Innovent takes giant step toward global innovation. The partnership demonstrates Innovent's strategic progression: Innovent has long sought…
2026 ASCO: IBI363 (Takeda R&D code TAK-928) PoC long-term follow-up shows robust survival in advanced IO-resistant NSCLC; >40%% of patients survived beyond…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Takeda licensed global rights (ex-Greater China) to two late-stage oncology candidates from Innovent plus option to license IBI3001. Innovent receives $1.2B upfront (including $100M equity investment) and up to $10.2B in milestones, total up to $11.4B. Largest China-outbound biopharma licensing deal of 2025. Closed December 4, 2025.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Innovent Biologics, Inc. (this deal) | 2025 | $11.4B | — |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2025 deals · Takeda Pharmaceutical Company Ltd. deals · Gastroenterology deals